TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in ...
Healthline

All About Tysabri’s Dosage

Tysabri (natalizumab) is a prescription drug that’s used to manage Crohn’s disease and certain kinds of multiple sclerosis (MS). The drug comes as an intravenous (IV) infusion. It’s usually given ...
Business Insider

Cellevolve Bio Receives FDA Clearance of IND Application and Orphan Drug Designation for CE-VST01-JC for the Treatment of Progressive Multifocal Leukoencephalopathy (PML)

CE-VST01-JC is an allogeneic, off-the-shelf, T cell therapy targeting the JC virus, the cause of PML, a rare, rapidly progressing, often fatal illness for which there are no approved treatment options ...
Medscape

PML Reported in Patient Receiving Ocrelizumab

Roche is investigating one case of progressive multifocal leukoencephalopathy (PML) in a patient with multiple sclerosis (MS) after treatment with ocrelizumab (Ocrevus). The company said that ...
FOX8 Cleveland

Cellevolve Bio Submits Investigational New Drug (IND) Application for Global Phase 2, Placebo-controlled Study of CE-VST01-JC for the Treatment of Progressive Multifocal ...

SAN FRANCISCO, Sept. 20, 2022 /PRNewswire/ -- Cellevolve Bio, Inc. ("the Company" or "Cellevolve"), a development and commercialization platform company focused on cell therapies, today announced the ...